You are now leaving the LillyMedical.com Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.
Diabetes Journal Publications
If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services below for further assistance.
Basaglar
Full Prescribing InformationLY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
Published Date: September 21, 2017
Publication Link
No Publications.
Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
Published Date: August 2, 2019
Publication Link
Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
Published Date: May 22, 2019
Publication Link
Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
Published Date: January 2, 2019
Publication Link
Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
Published Date: July 23, 2018
Publication Link
Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
Published Date: May 31, 2018
Publication Link
Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials
Published Date: May 8, 2018
Publication Link
Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study
Published Date: March 14, 2018
Publication Link
Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
Published Date: March 30, 2017
Publication Link
Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study
Published Date: April 23, 2020
Publication Link
Glucagon
Full Prescribing InformationNo Publications.
No Publications.
NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE
Published Date: April 15, 2020
Publication Link
Nasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study
Published Date: March 1, 2020
Publication Link
A phase 3 multicenter, open‐label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting
Published Date: March 22, 2018
Publication Link
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
Published Date: March 22, 2018
Publication Link
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial
Published Date: November 19, 2017
Publication Link
Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
Published Date: May 30, 2017
Publication Link
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Published Date: February 16, 2016
Publication Link
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Published Date: December 17, 2015
Publication Link
No Publications.
Humalog
Humalog® U-100 | Full Prescribing InformationHumalog® U-200 | Full Prescribing Information
Humalog® MIX50/50™ | Full Prescribing Information
Humalog® MIX75/25™ | Full Prescribing Information
No Publications.
No Publications.
No Publications.
Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis
Published Date: May 17, 2019
Publication Link
Fasting experience of patients with Type 2 diabetes mellitus on insulin therapy during Ramadan: VISION Ramadan substudy
Published Date: February 27, 2019
Publication Link
Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region
Published Date: January 14, 2019
Publication Link
Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial
Published Date: March 24, 2018
Publication Link
When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
Published Date: December 15, 2017
Publication Link
CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents
Published Date: July 13, 2017
Publication Link
Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications
Published Date: July 3, 2017
Publication Link
Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial
Published Date: May 24, 2017
Publication Link
Humulin
Humulin® R (U-100) | Full Prescribing InformationHumulin® R (U-500) | Full Prescribing Information
Humulin® 70/30 | Full Prescribing Information
Humulin® N U-100 | Full Prescribing Information
No Publications.
No Publications.
Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
Published Date: December 22, 2019
Publication Link
No Publications.
Lyumjev
Full Prescribing InformationPharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
Published Date: May 29, 2020
Publication Link
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
Published Date: May 29, 2020
Publication Link
Ultra Rapid Lispro Lowers Postprandial Glucose and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs: A Phase 1 Randomized, Crossover Study
Published Date: May 21, 2020
Publication Link
Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes
Published Date: December 9, 2019
Publication Link
No Publications.
Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26‐Week PRONTO‐T1D Study
Published Date: June 15, 2020
Publication Link
Ultra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-Study
Published Date: May 21, 2020
Publication Link
No Publications.
Trulicity
Full Prescribing InformationNo Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide
Published Date: March 29, 2017
Publication Link
Once‐weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion
Published Date: February 17, 2017
Publication Link
Change in HbA1c Across the Baseline HbA1c Range in Type 2 DiabetesPatients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019
Publication Link
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018
Publication Link
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017
Publication Link
No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer
Published Date: July 29, 2017
Publication Link
Assessment of PancreasSafety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Published Date: March 10, 2017
Publication Link
Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
Published Date: April 10, 2020
Publication Link
Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c
Published Date: April 3, 2020
Publication Link
Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
Published Date: March 26, 2020
Publication Link
Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
Published Date: November 23, 2019
Publication Link
Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
Published Date: July 31, 2019
Publication Link
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Published Date: July 13, 2019
Publication Link
Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
Published Date: June 21, 2019
Publication Link
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III study
Published Date: May 18, 2019
Publication Link
Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019
Publication Link
Weight loss in patients with type 2 diabetes receiving once‐weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post‐hoc analysis of the AWARD‐4 study across baseline body mass index subgroups
Published Date: March 15, 2019
Publication Link
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
Published Date: February 14, 2019
Publication Link
Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
Published Date: February 3, 2019
Publication Link
Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trial
Published Date: August 21, 2018
Publication Link
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Published Date: June 14, 2018
Publication Link
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018
Publication Link
Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
Published Date: March 23, 2018
Publication Link
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Published Date: February 23, 2018
Publication Link
Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes
Published Date: December 20, 2017
Publication Link
Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes
Published Date: September 14, 2017
Publication Link
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017
Publication Link
No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer
Published Date: July 29, 2017
Publication Link
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
Published Date: June 12, 2017
Publication Link
Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide
Published Date: June 1, 2017
Publication Link
Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD ‐9)
Published Date: April 10, 2017
Publication Link
Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan
Published Date: March 29, 2017
Publication Link
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Published Date: March 10, 2017
Publication Link
Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment
Published Date: March 7, 2017
Publication Link
Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019
Publication Link
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018
Publication Link
Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
Published Date: March 23, 2018
Publication Link
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017
Publication Link
Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD ‐9)
Published Date: April 10, 2017
Publication Link
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
